 Clifford Greyson
Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Dysfunction, Right | 4 | 2010 | 236 | 0.750 |
Why?
| | Ventricular Function, Right | 3 | 2011 | 283 | 0.680 |
Why?
| | Calpain | 2 | 2012 | 59 | 0.660 |
Why?
| | Heart Failure | 5 | 2012 | 2222 | 0.580 |
Why?
| | Myocardial Contraction | 7 | 2013 | 343 | 0.560 |
Why?
| | Myocardial Reperfusion Injury | 5 | 2013 | 134 | 0.510 |
Why?
| | Swine | 20 | 2017 | 775 | 0.420 |
Why?
| | Hypertension, Pulmonary | 4 | 2012 | 1903 | 0.420 |
Why?
| | Pulmonary Heart Disease | 1 | 2012 | 6 | 0.400 |
Why?
| | Heart Ventricles | 7 | 2012 | 792 | 0.390 |
Why?
| | Talin | 1 | 2012 | 9 | 0.390 |
Why?
| | Hemodynamics | 11 | 2012 | 1114 | 0.380 |
Why?
| | Cardiotonic Agents | 4 | 2008 | 126 | 0.370 |
Why?
| | Pulmonary Circulation | 2 | 2012 | 430 | 0.360 |
Why?
| | Adenosine Triphosphate | 5 | 2017 | 487 | 0.330 |
Why?
| | Adenosine Diphosphate | 2 | 2008 | 79 | 0.310 |
Why?
| | Coronary Occlusion | 1 | 2008 | 19 | 0.300 |
Why?
| | Ventricular Fibrillation | 3 | 2017 | 60 | 0.300 |
Why?
| | Prodrugs | 1 | 2008 | 49 | 0.290 |
Why?
| | Ventricular Function | 2 | 2008 | 61 | 0.290 |
Why?
| | Ventricular Pressure | 1 | 2007 | 48 | 0.280 |
Why?
| | Folic Acid | 1 | 2008 | 186 | 0.270 |
Why?
| | Intensive Care Units | 1 | 2012 | 803 | 0.270 |
Why?
| | Myocardial Ischemia | 5 | 2017 | 263 | 0.250 |
Why?
| | Heart | 6 | 2009 | 660 | 0.240 |
Why?
| | Acute Disease | 4 | 2012 | 1008 | 0.240 |
Why?
| | Thiazolidinediones | 4 | 2012 | 137 | 0.220 |
Why?
| | Metabolic Syndrome | 3 | 2013 | 354 | 0.220 |
Why?
| | PPAR gamma | 3 | 2012 | 183 | 0.200 |
Why?
| | Cardiac Output | 2 | 2012 | 164 | 0.180 |
Why?
| | Dipeptides | 2 | 2012 | 50 | 0.160 |
Why?
| | Animals | 24 | 2017 | 37009 | 0.150 |
Why?
| | Swine, Miniature | 3 | 2013 | 82 | 0.150 |
Why?
| | Energy Metabolism | 5 | 2004 | 895 | 0.140 |
Why?
| | Coronary Circulation | 7 | 2004 | 141 | 0.140 |
Why?
| | Myocardium | 8 | 2004 | 1004 | 0.130 |
Why?
| | Systole | 4 | 2001 | 191 | 0.120 |
Why?
| | Heart Function Tests | 2 | 2013 | 61 | 0.110 |
Why?
| | Disease Models, Animal | 8 | 2013 | 4295 | 0.110 |
Why?
| | Dobutamine | 3 | 2000 | 39 | 0.100 |
Why?
| | Metformin | 1 | 2017 | 328 | 0.100 |
Why?
| | Insulin Resistance | 2 | 2013 | 1198 | 0.100 |
Why?
| | Actinin | 1 | 2012 | 13 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2013 | 203 | 0.090 |
Why?
| | Diastole | 3 | 2001 | 150 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 346 | 0.090 |
Why?
| | Dietary Fats | 2 | 2013 | 301 | 0.090 |
Why?
| | Uncertainty | 1 | 2012 | 127 | 0.090 |
Why?
| | Central Venous Pressure | 1 | 2011 | 14 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 119 | 0.090 |
Why?
| | Hypertension | 1 | 2000 | 1293 | 0.090 |
Why?
| | Reperfusion Injury | 2 | 2005 | 279 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 414 | 0.080 |
Why?
| | Ischemia | 1 | 2012 | 408 | 0.080 |
Why?
| | Hyperhomocysteinemia | 1 | 2008 | 27 | 0.080 |
Why?
| | Premedication | 1 | 2008 | 44 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 834 | 0.070 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 173 | 0.070 |
Why?
| | KATP Channels | 1 | 2008 | 20 | 0.070 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2008 | 184 | 0.070 |
Why?
| | Obesity | 2 | 2013 | 2974 | 0.070 |
Why?
| | Densitometry | 1 | 2007 | 34 | 0.070 |
Why?
| | Spectrin | 1 | 2007 | 14 | 0.070 |
Why?
| | Desmin | 1 | 2007 | 24 | 0.070 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2007 | 38 | 0.070 |
Why?
| | Troponin | 1 | 2007 | 51 | 0.070 |
Why?
| | Purines | 1 | 2008 | 176 | 0.070 |
Why?
| | Insulin | 3 | 2013 | 2398 | 0.070 |
Why?
| | Rats, Wistar | 1 | 2008 | 457 | 0.070 |
Why?
| | Ultrasonography | 1 | 2011 | 750 | 0.070 |
Why?
| | Hypoglycemic Agents | 3 | 2012 | 1285 | 0.060 |
Why?
| | Heart-Assist Devices | 1 | 2012 | 550 | 0.060 |
Why?
| | Calcium-Binding Proteins | 1 | 2007 | 218 | 0.060 |
Why?
| | Fenofibrate | 1 | 2005 | 29 | 0.060 |
Why?
| | Phosphocreatine | 3 | 1994 | 47 | 0.060 |
Why?
| | Fetus | 1 | 2010 | 807 | 0.060 |
Why?
| | Protein Processing, Post-Translational | 1 | 2007 | 471 | 0.060 |
Why?
| | Oxygen Consumption | 4 | 1996 | 684 | 0.060 |
Why?
| | Blood Pressure | 4 | 2009 | 1776 | 0.060 |
Why?
| | Ventricular Function, Left | 4 | 2004 | 540 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2008 | 914 | 0.050 |
Why?
| | Phosphorylation | 3 | 2013 | 1762 | 0.050 |
Why?
| | Glucose | 3 | 2013 | 1018 | 0.050 |
Why?
| | Female | 15 | 2017 | 73160 | 0.050 |
Why?
| | Prognosis | 1 | 2011 | 4030 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2008 | 923 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2008 | 1307 | 0.050 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2004 | 159 | 0.050 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 59 | 0.050 |
Why?
| | Humans | 6 | 2012 | 137509 | 0.050 |
Why?
| | Diacetyl | 1 | 2001 | 7 | 0.050 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 220 | 0.040 |
Why?
| | Myocardial Infarction | 1 | 2008 | 1045 | 0.040 |
Why?
| | Apoptosis | 1 | 2010 | 2557 | 0.040 |
Why?
| | Hexamethonium | 1 | 2000 | 4 | 0.040 |
Why?
| | Cytokines | 2 | 2005 | 2095 | 0.040 |
Why?
| | Atropine | 1 | 2000 | 24 | 0.040 |
Why?
| | Dilatation, Pathologic | 1 | 2000 | 61 | 0.040 |
Why?
| | Pericardium | 1 | 2000 | 56 | 0.040 |
Why?
| | Rats | 1 | 2008 | 5676 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2113 | 0.040 |
Why?
| | Potassium | 1 | 2000 | 151 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2013 | 437 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2000 | 160 | 0.040 |
Why?
| | Infant, Newborn | 1 | 2010 | 6058 | 0.040 |
Why?
| | Linear Models | 1 | 2000 | 850 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 1995 | 619 | 0.030 |
Why?
| | Citrate (si)-Synthase | 1 | 2017 | 60 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2000 | 528 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 154 | 0.030 |
Why?
| | Signal Transduction | 1 | 2009 | 5096 | 0.030 |
Why?
| | Male | 7 | 2017 | 67715 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 197 | 0.030 |
Why?
| | Diet | 2 | 2013 | 1273 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1718 | 0.030 |
Why?
| | Phosphorus | 1 | 1995 | 97 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1995 | 272 | 0.030 |
Why?
| | Chromans | 2 | 2004 | 25 | 0.030 |
Why?
| | Pulmonary Artery | 1 | 2000 | 1083 | 0.030 |
Why?
| | Stroke Volume | 1 | 1997 | 619 | 0.030 |
Why?
| | Acyl Coenzyme A | 1 | 2013 | 31 | 0.030 |
Why?
| | Hydroxy Acids | 1 | 2012 | 4 | 0.020 |
Why?
| | Decanoic Acids | 1 | 2012 | 8 | 0.020 |
Why?
| | Ischemic Preconditioning, Myocardial | 1 | 2012 | 30 | 0.020 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 37 | 0.020 |
Why?
| | Glyburide | 1 | 2012 | 32 | 0.020 |
Why?
| | Cardiolipins | 1 | 2013 | 85 | 0.020 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 115 | 0.020 |
Why?
| | Biopsy | 1 | 1995 | 1132 | 0.020 |
Why?
| | Blood Glucose | 2 | 2013 | 2183 | 0.020 |
Why?
| | Arteries | 1 | 2013 | 269 | 0.020 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 184 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 413 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 322 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2012 | 245 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 494 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 241 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 366 | 0.020 |
Why?
| | Adult | 1 | 2010 | 37818 | 0.020 |
Why?
| | Time Factors | 1 | 1997 | 6817 | 0.020 |
Why?
| | PPAR alpha | 1 | 2005 | 59 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2004 | 2838 | 0.020 |
Why?
| | Hypolipidemic Agents | 1 | 2005 | 92 | 0.010 |
Why?
| | Heart Rate | 2 | 2001 | 831 | 0.010 |
Why?
| | Sus scrofa | 1 | 2004 | 52 | 0.010 |
Why?
| | alpha-Tocopherol | 1 | 2004 | 33 | 0.010 |
Why?
| | Isoproterenol | 2 | 1994 | 116 | 0.010 |
Why?
| | Thiazoles | 1 | 2003 | 123 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 41 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2001 | 46 | 0.010 |
Why?
| | Antioxidants | 1 | 2004 | 577 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 2003 | 331 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 389 | 0.010 |
Why?
| | Drug Combinations | 1 | 2000 | 344 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1999 | 434 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 195 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 412 | 0.010 |
Why?
| | Lactic Acid | 1 | 1996 | 306 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1996 | 474 | 0.010 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1994 | 30 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1994 | 174 | 0.010 |
Why?
| | Lactates | 1 | 1994 | 85 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2615 | 0.010 |
Why?
| | NAD | 1 | 1994 | 77 | 0.010 |
Why?
| | Glycine | 1 | 1994 | 175 | 0.010 |
Why?
| | Mitochondria, Heart | 1 | 1994 | 100 | 0.010 |
Why?
| | Oxidative Phosphorylation | 1 | 1994 | 193 | 0.010 |
Why?
| | Heparin | 1 | 1994 | 259 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1992 | 66 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2005 | 10821 | 0.010 |
Why?
|
|
Greyson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|